Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript
Delcath Systems, Inc. (NASDAQ:DCTH ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Vojislav Vukovic - Chief Medical Officer Conference Call Participants John Newman - Canaccord Genuity Corp Marie Thibault - BTIG Sudan Loganathan - Stephens Bill Maurer - ClearStreet Yale Jen - Laidlaw & Company Chase Knickerbocker - Craig-Hallum Capital Group Swayampakula Ramakanth - H.C. Wainwright Operator Greetings and welcome to the Delcath Systems' Fourth Quarter 2024 Earnings Conference Call.
Delcath Systems, Inc. (DCTH) Beats Q4 Earnings and Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.48 per share a year ago.
Are You Looking for a Top Momentum Pick? Why Delcath Systems, Inc. (DCTH) is a Great Choice
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 33.74%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 33.7% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Biotech walks a 'tightrope' amid unclear funding, regulations
Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street senior equity analyst and director of research, Mara Goldstein, sits down with Julie Hyman and Josh Lipton on Market Domination to discuss how to play the biotech sector as Trump's second term in the White House is underway.
Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Delcath Begins Platform Expansion With Two Phase 2 Trials
Delcath's Q3 US sales hit $10 million. This unlocked $25 million in cash from its Tranche B Warrants, which will fund its Phase 2 trials for mCRC and mBC. HEPZATO KIT's hospital rollout is progressing well. Delcath plans to end the year with 15 centers and end 2025 with 30. Treatment has gone well at UCLA. Three retrospective clinical trials and the FOCUS trial's subgroup analysis add to the growing body of evidence which shows PHP's effectiveness in treating mUM and other tumor types.
Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 active treatment centers and plans to reach 30 by the end of 2025. Promising growth drivers include new cancer indications for HEPZATO, potential label expansion, and combining with immune checkpoint inhibitors.
Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript
Delcath Systems Inc (NASDAQ:DCTH ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Vojislav Vukovic - Chief Medical Officer Conference Call Participants Sudan Loganathan - Stephens Swayampakula Ramakanth - H.C. Wainwright John Newman - Canaccord Genuity Corp Yale Jen - Laidlaw & Company Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings and welcome to the Delcath Systems' Third Quarter 2024 Earnings Call.
Delcath Systems, Inc. (DCTH) Reports Q3 Loss
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.61 per share a year ago.
Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 96.84%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 96.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
